This article is more than 5 years old. Information may no longer be current.

Alimera to sell $37.5 million of common stock in private placement

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Alimera Sciences has entered into a securities purchase agreement with non-affiliated institutional investors to purchase approximately $37.5 million of its common stock in a private placement, according to a company press release.
An aggregate of 6,250,000 shares of common stock will be sold for $6.00 per share, the release said.

Proceeds will be put toward general corporate and working capital purposes, including the continued commercialization of Iluvien in Europe and ongoing pursuit of Food and Drug Administration approval of Iluvien in the U.S., according to the release.

The shares of common stock were offered only to accredited investors. Alimera has agreed to file a registration statement with the Securities Exchange Commission covering the common stock purchased by the investors. Any offering of Alimera's securities under the resale registration statement will be made only by means of a prospectus, according to the release.